Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review
- PMID: 34040477
- PMCID: PMC8141405
- DOI: 10.2147/AHMT.S303456
Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review
Abstract
Neurofibromatosis type 1 (NF1) is an incurable genetic condition that frequently includes the development of plexiform neurofibromas (PNs) in patients. A systematic literature review was conducted to identify data on the natural history, disease burden, and treatment patterns among patients diagnosed with NF1 and PN, as well as to identify evidence gaps in these areas. MEDLINE and MEDLINE In-Process, Embase, and Cochrane Library Searches were searched using predefined terms. Potential references underwent two phases of screening by two independent researchers. A total of 39 references focusing on populations of patients with both NF1 and PN were included in this review. The wide range of PN-related complications creates a substantial quality-of-life (QOL) burden for patients, including pain, social functioning, physical function impact, stigma, and emotional distress. The severe burden of NF1 with PN on the QOL of patients demonstrates the high unmet need for an effective treatment option that can reduce tumor burden and improve QOL. The heterogeneity of measurement tools used to evaluate QOL and the gap in data evaluating the health economic burden of PN should be the focus of future research.
Keywords: natural history; neurofibromatosis type 1; plexiform neurofibromas; quality of life; review.
© 2021 Copley-Merriman et al.
Conflict of interest statement
CCM and MJ are full-time employees of RTI Health Solutions, an independent nonprofit research organization, which received funding pursuant to a contract from Merck to conduct the study, which is the subject of this manuscript. XY is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and holds shares in Merck & Co., Inc., Kenilworth, NJ, USA stock. SSS was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, at the time the study was conducted. SA and HKY are employees of AstraZeneca and hold shares in AstraZeneca stock.
References
-
- Genetics Home Reference. Neurofibromatosis type 1. Available from: https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1#statistics.. Accessed May 3, 2020.
-
- Menon AG, Gusella JF, Seizinger BR. Progress towards the isolation and characterization of the genes causing neurofibromatosis. Cancer Surv. 1990;9(4):689–702. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
